Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • Triple negative • Journal Club ft. NEJM publications • Breast Cancer, Metastatic
How has the ASCENT trial impacted your management of previously treated metastatic TNBC?
Are there specific patient cohorts in whom you will more preferentially use sacituzumab govitecan?
Can data from ASCENT be applied to patients with CNS metastases?
Answer from: Medical Oncologist at Academic Institution
The phase III ASCENT trial demonstrated improved progression-free survival and overall survival with sacituzumab govitecan over single-agent chemotherapy of physician’s choice (TPC) in metastatic triple-negative breast cancer (mTNBC). All the sub-groups derived benefit, including <65 vs >...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Using sacituzumab 2nd line when possible, definitely third line.
Answer from: Medical Oncologist at Community Practice
The approval of sacituzumab has given us a powerful tool in our bag of options for TNBC. In the ASCENT trial, remember that treatment of physician’s choice (TPC) chemotherapy performed very poor with a mPFS in the TPC arm of less than 2 months. Having a drug that not only improves PFS (1....